Cambrex Corporation (CBM) CEO Sells $219,840.00 in Stock
Cambrex Corporation (NYSE:CBM) CEO Steven M. Klosk sold 4,000 shares of the business’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $54.96, for a total transaction of $219,840.00. Following the sale, the chief executive officer now owns 87,328 shares in the company, valued at $4,799,546.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of Cambrex Corporation (NYSE CBM) traded up 0.18% during midday trading on Tuesday, hitting $55.10. The stock had a trading volume of 441,535 shares. The company has a market cap of $1.80 billion, a P/E ratio of 20.07 and a beta of 2.28. Cambrex Corporation has a one year low of $38.30 and a one year high of $62.95. The firm has a 50 day moving average of $52.54 and a 200-day moving average of $55.32.
Cambrex Corporation (NYSE:CBM) last issued its quarterly earnings results on Friday, August 4th. The biotechnology company reported $0.76 EPS for the quarter, meeting analysts’ consensus estimates of $0.76. The company had revenue of $134.55 million for the quarter, compared to analyst estimates of $136.82 million. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The company’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same period last year, the company earned $0.68 earnings per share. On average, analysts forecast that Cambrex Corporation will post $3.08 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in Cambrex Corporation by 0.5% during the 2nd quarter. BlackRock Inc. now owns 4,023,607 shares of the biotechnology company’s stock valued at $240,409,000 after buying an additional 20,652 shares during the period. Vanguard Group Inc. raised its position in shares of Cambrex Corporation by 4.6% during the 1st quarter. Vanguard Group Inc. now owns 3,138,934 shares of the biotechnology company’s stock worth $172,799,000 after buying an additional 139,010 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Cambrex Corporation by 0.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,330,254 shares of the biotechnology company’s stock worth $79,483,000 after buying an additional 11,762 shares in the last quarter. Congress Asset Management Co. MA raised its position in shares of Cambrex Corporation by 8.7% during the 2nd quarter. Congress Asset Management Co. MA now owns 1,297,023 shares of the biotechnology company’s stock worth $77,497,000 after buying an additional 103,900 shares in the last quarter. Finally, FMR LLC raised its position in shares of Cambrex Corporation by 19.1% during the 2nd quarter. FMR LLC now owns 1,070,645 shares of the biotechnology company’s stock worth $63,971,000 after buying an additional 171,559 shares in the last quarter. Hedge funds and other institutional investors own 98.28% of the company’s stock.
A number of equities analysts have recently weighed in on the stock. Zacks Investment Research cut shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. BidaskClub cut shares of Cambrex Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. Finally, ValuEngine cut shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. Cambrex Corporation has a consensus rating of “Hold” and an average price target of $64.00.
About Cambrex Corporation
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.